Prostamax is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Pro), one of a set of short "bioregulator" peptides studied in Russia and Georgia, described as targeting the prostate. It is not approved in the US, and we found no published study that gave it to people.
Also known as: Lys-Glu-Asp-Pro.
There is no approved product and no labeled strength we could confirm. The studies we found used cells and rat tissue, so there is no amount studied in people.
Prostamax is not an approved drug in the US, and we found no Prostamax product in Drugs@FDA.
All the studies we found are lab studies. In white blood cells from people aged 75 to 86, grown in a dish (Dzhokhadze 2012), prostamax loosened tightly packed chromatin, which the authors read as reactivating genes switched off with age. A heat-based study of human white blood cells (Meskhi 2004) found small changes in chromatin structure. In rat tissue (Zakutskiĭ 2006), it increased cell growth in prostate tissue, and the authors suggested these peptides could be used clinically; no human study followed in what we found.
This work comes from a few small labs and was published mostly in Russian and Georgian journals. Results in cells and rat tissue often do not carry over to people.
We could not find a published human half-life for this compound. The studies we found were in cells and rats, so we do not list one.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator